View metadata, citation and similar papers at core.ac.uk

brought to you by CORE

provided by St George's Online Research Archive

Next-generation sequencing of AV Nodal Reentrant Tachycardia patients identifies broad spectrum of variants in ion channel genes

Running title: Atrioventricular nodal reentry tachycardia genetic

Laura Andreasen[1,2†], MD, Gustav Ahlberg[1,2†], MSc, Chuyi Tang[1], MD, Charlotte Andreasen[2], MD, Jacob P. Hartmann[1,2], BSc, Jacob Tfelt-Hansen[2,3], MD, DMSc, Elijah R. Behr[4], MD, PhD, Steen Pehrson[3], MD, DMSc, Stig Haunsø[1,2,3], MD, DMSc, LuCamp[5], Peter E. Weeke[2], MD, PhD, Thomas Jespersen[1], MSc, PhD, DMSc, Morten S. Olesen[1,2,3‡], MSc, PhD, Jesper H. Svendsen[1,2,3‡], MD, DMSc.

[1]Danish National Research Foundation Centre for Cardiac Arrhythmia, Copenhagen, Denmark

[2]Laboratory for Molecular Cardiology & Department of Cardiology, The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

[3]Department of Clinical Medicine, Faculty of Medicine and Health Science, University of Copenhagen, Copenhagen, Denmark

[4]Cardiology Clinical Academic Group, St George's University of London, London SW17 0RE, UK

[5]The Lundbeck Foundation Centre for Applied Medical Genomics in Personalized Disease Prediction, Prevention and Care, Copenhagen, Denmark

[†,‡]These authors contributed equally to this work.

Corresponding author

Morten Salling Olesen, MSc, PhD

Laboratory for Molecular Cardiology, Rigshospitalet

Henrik Harpestrengs Vej 4C, 2100 Copenhagen Ø, Denmark

Phone: +45 35456506, Fax: +45 35456500

Email: morten.salling.olesen@gmail.com

Total word count: 4.389

Disclosures: None declared.

Abstract

Atrioventricular nodal reentry tachycardia (AVNRT) is the most common form of regular paroxysmal supraventricular tachycardia. This arrhythmia affects women twice as frequently as men, and is often diagnosed in patients below 40 years of age. Familial clustering, early onset of symptoms, and lack of structural anomaly indicate involvement of genetic factors in AVNRT pathophysiology.

We hypothesized that AVNRT patients have a high prevalence of variants in genes that are highly expressed in the atrioventricular conduction axis of the heart and potentially involved in arrhythmic diseases.

Next-generation sequencing of 67 genes was applied to the DNA profile of 298 AVNRT patients and 10 AVNRT family members using HaloPlex Target Enrichment System.

In total, we identified 229 variants in 60 genes; 215 missenses, four frame shifts, four codon deletions, three missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these were not present in the Exome Aggregation Consortium (ExAC) database. Furthermore, we report two AVNRT families with co-segregating variants. Seventy-five of 284 AVNRT patients (26.4%) and three family members to different AVNRT probands had one or more variants in genes affecting the sodium handling. Fifty-four out of 284 AVNRT patients (19.0%) had variants in genes affecting the calcium handling of the heart. We furthermore find a large proportion of variants in the *HCN1-4* genes. We did not detect a significant enrichment of rare variants in the tested genes.

This could be an indication that AVNRT might be an electrical arrhythmic disease with abnormal sodium and calcium handling.

Keywords

Sodium, tachyarrhythmia, ion channel, electrophysiology, genetics

55 **Introduction**

56 Atrioventricular nodal reentry tachycardia (AVNRT) is a supraventricular tachycardia (SVT), originating
57 from the atrio-ventricular node (AVN) region [1]. It is the most common form of regular paroxysmal
58 supraventricular tachycardia [2]. Women are affected twice as frequently as men, and the fact that this
59 arrhythmia is often diagnosed in women under 40 years of age suggests a genetic component of the
60 disease [3,4]. The symptoms of SVT are typically related to the sudden occurrence of tachycardia, with
61 palpitations being the most common symptom, possibly accompanied by chest discomfort, dyspnoea,
62 anxiety, and light-headedness. Some patients occasionally experience an unregulated drop in blood
63 pressure at the onset of the tachycardia, resulting in syncope, particularly at high frequency rates and
64 during prolonged episodes of tachycardia [5].

65 AVNRT occurs when a reentry circuit forms within or in close proximity to the AV node. Two areas with
66 diverse electrophysiological conduction properties (termed pathways) have been found implicated in
67 the reentry circuits in AVNRT patients, *the fast pathway* and *the slow pathway*; both located in the right
68 atrium. These pathways show opposite electrophysiological properties, with respect to conduction
69 velocity and duration of the refractory period, resulting in different relations between the P wave and
70 the QRS complex on the electrocardiogram. In both cases, the P wave appearance is negative in leads II,
71 III, and aVF [6].

72 The presence of this diversity in the electrophysiological properties in the area around the AVN is
73 termed dual AV nodal conduction. Dual AV nodal conduction is considered a congenital functional
74 abnormality developed during cardiogenesis in foetal life [7]. In 2000, Lu et al. described the occurrence of
75 dual AV nodal conduction in monozygotic twins [8]. In addition, Hayes et al. described several families
76 with AVNRT among first-degree-relatives. The authors were also able to induce typical AVNRT and to
77 demonstrate dual AV nodal conduction in 12 of the 13 studied family members from six different
78 families [7]. A recent study by Michowitz et al. reported a high familial AVNRT prevalence among patients
79 who underwent radiofrequency ablation [9]. These studies indicate that there could be a hereditary
80 component in the development of AVNRT. Familial clustering, early onset of symptoms, and the lack of
81 structural anomaly indicate involvement of genetic factors, as seen in other arrhythmias [10]. Several

82 cardiac arrhythmias have previously been associated with ion channel variants [11], and this may be a
83 possible pathophysiological mechanism of AVNRT as well. Identifying possible disease causing and
84 disease modifying genetic variants could potentially reveal new insight in the pathophysiology of AVNRT
85 and have a role in future diagnosis and risk assessment.
86 We hypothesized that AVNRT is an ion channel disease, and that AVNRT patients have a high prevalence
87 of variants in genes, that are highly expressed in the atrioventricular conduction axis of the heart and
88 are known to be involved in the pathophysiology of other arrhythmic diseases.

89

90 **Subjects and Methods**

91 **Study population**

92 Study participants (probands) were identified among patients treated with radiofrequency catheter
93 ablation at the Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, in the period
94 from 2010-2012, with an age >18 years and <60 years. Furthermore, 10 relatives of these probands with
95 a history of AVNRT were included. Upon inclusion a blood sample, a 12 lead ECG, and a cardiac history
96 were taken and patients were questioned about their family history.

97 The study conforms to the principles outlined in the Declaration of Helsinki, and was approved by the
98 Scientific Ethics Committee of Copenhagen and Frederiksberg (Protocol reference number: H-A-2008-
99 004).

100

101 **Control group**

102 The control group consisted of 383 healthy men and women between 55 and 75 years of age and
103 without history of cardiovascular disease or stroke from the Copenhagen Holter Study [12].
104 The study protocol was approved by the local ethics committee (KF 01 313322, KF 01 25304).

105

106 **Target genes**

107 We selected 67 target genes. The genes were selected based on the following criteria: 1) PR interval
108 associated genes identified by genome-wide association studies (GWAS) [13], 2) genes selected based on
109 cardiac expression levels [14], 3) plausible genes based on protein function and association with other
110 arrhythmic diseases. Selected genes are listed in **Table 1**.

111

112 **Next-Generation Sequencing**

113 DNA was extracted from whole blood that had been stored at -80°C using the QIAamp DNA Blood Mini
114 and Maxi kits (Qiagen, Hilden, Germany).
115 We developed a custom design based on HaloPlex technology (Agilent Technologies, Inc., Santa Clara,
116 CA, USA) to perform high-throughput sequencing of the coding regions of 67 genes.

Next-generation sequencing (NGS) was applied using HaloPlex Target Enrichment System (Agilent Technologies, Inc., Santa Clara, CA, USA) on 200 ng DNA from the 298 probands and 10 family members with AVNRT according to the manufacturer's instructions [15]. In brief, patient DNA was fragmented by endonucleases and hybridized to biotinylated gene specific probes incorporating Illumina paired-end sequencing motifs and indexed primers. Hybridised molecules were captured by magnetic beads, PCR amplified, and sequenced with the MiSeq system (Illumina Inc., San Diego, CA, USA).

Microarray Genotyping

Genotyping was done using Infinium PsychArray BeadChip. This microarray has ~590,000 fixed markers. SNP calling and QC and was done following Broads Institute's recommendations.

***In vitro* Electrophysiology**

See **Supplementary**.

Bioinformatics and Data analyses

Raw reads were aligned to reference genome GRCH37.p13/hg19 with Burrows-Wheelers Aligner, after trimming adapter sequences and filtering for poor quality reads. Genome Analysis Toolkit (GATK) v3.7 was used for indel realignment and base quality recalibration in the targeted regions.

Variants were called with Unifiedgenotyper/GATK v3.7 following the GATK of Broad Institute's current guidelines [16], see **Figure 1** for bioinformatics pipeline.

For details on settings and filtering steps, see **Supplementary Material.**

Genotype array data were used to infer ethnicity and relatedness performed in R with R-package SNPRelate [17], see **Supplementary Material.**

Statistical Analyses

We performed a burden test on the targeted genes with ethnically matched and unrelated subjects in the AVNRT cohort (considered subjects n=284) and the control group (considered subjects n=377). Only the intersecting region between the two capture kits and exons with sufficient coverage were

considered in the tests, see **Supplementary Figure 1, 2, 3 and Supplementary text**. The intersect region spanned 30 genes, listed in **Supplementary Table 7**.

Variants with annotation of a putative deleterious impact were included, see **Supplementary Table 3** (e.g. missense, codon deletions). Variants tagged as “COMMON” in dbSnp b.141 were excluded.

We performed two rounds of burden testing. First, variants found in the Exome Aggregation Consortium (ExAC) database with a minor allele frequency (MAF) above 0.5% in any of the ExAC populations were excluded, second, this threshold was set to 0.1%. The statistical method SKAT-O was applied in the burden tests, using R package GENESIS [18,19]. A Bonferroni corrected p-value < 0.05 was considered significant.

Data availability

Data on reported variants are made available to the European Bioinformatics Institute (EBI) database The European Genome-phenome Archive (EGA) (https://www.ebi.ac.uk/ega/, study accession EGAS00001002745).

Results

Two-hundred-and-eighty-four patients with a median onset of AVNRT related symptoms at 24 years of age were included after excluding ethnic outliers and subjects with unreported relatedness (70% females). Clinical data of the patient population (probands) are shown in **Table 2**.

We identified 229 variants in 184 patients; 215 missense, four frame shift, four codon deletions, three missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these were not present in ExAC. The results of the NGS are shown in **Supplementary Table 4**.

Variants in sodium handling genes

There were 75 out of 284 AVNRT patients (26.4%) and three family members of three different AVNRT probands who had one or more variants in genes affecting the sodium handling.

We identified variants in *SCN3A* (n = 3, ENSG00000166257.4), *SCN5A* (n = 7, ENSG00000153253.11), *SCN10A* (n = 16, ENSG00000185313.6), *SCN8A* (n = 3, ENSG00000196876.9), *SCN4A* (n = 12, ENSG00000007314.7), *SCN1A* (n = 3, ENSG00000144285.11), *SCN2B* (n = 1, ENSG00000149575.5), and *SCN9A* (n = 12, ENSG00000169432.10).

Variants in calcium handling genes

Fifty-four of 284 AVNRT patients (19.0%) had variants in genes affecting the calcium handling of the heart. We identified variants in *RYR2* (n = 11, ENSG00000198626.11), *RYR3* (n = 16, ENSG00000198838.7), *CACNB2* (n = 2, ENSG00000165995.14), *ATP2A2* (n = 2, ENSG00000174437.12), *CACNA1C* (n = 5, ENSG00000151067.16), *CACNA1D* (n = 13, ENSG00000157388.9), *CACNA1I* (n = 7, ENSG00000100346.13), and *CACNA1G* (n = 3, ENSG00000006283.13).

Variants in the *HCN1-4* genes

Thirteen AVNRT patients carried variants in the hyperpolarization-activated and cyclic nucleotide-gated (HCN) channel genes *HCN1* (n = 5, ENSG00000164588.4), *HCN2* (n = 1, ENSG00000099822.2), *HCN3* (n = 5, ENSG00000263324.1), and *HCN4* (n = 2, ENSG00000138622.3).

Variants in *KCNE3*

Three variants with a total allele count of four were found in the *KCNE3* (ENSG00000175538.6) gene encoding the voltage-gated potassium channel K_v.

Family studies

Six families were identified with AVNRT reported in two or more family members. In two of these families, variants within the 67 screened genes where found (**Figure 2**). The proband carrying the c.6010T>C (p.(Phe2004Leu), ENST00000413689) variant in *SCN5A* and the c.2623C>T (p.(Pro875Ser), ENST00000435607) variant in *SCN4A* had a mother with AVNRT who carried the *SCN4A* variant and a sister with AVNRT who carried both the *SCN5A* and the *SCN4A* variant. Furthermore, the mother and the sister with AVNRT both carried the *RYR3* variant c.3598C>T (p.(Arg1200Cys), ENST00000389232).
The proband carrying the c.233C>T (p.(Thr78Met, ENST00000343849) variant in *CAV3* had a mother with AVNRT who carried the same variant.
For pedigrees of the four AVNRT families without found variants in the 67 screened genes, see **Supplementary Figure 6**.

Electrophysiological characterization of the *SCN5A* variants c.1381C>T and c.1576C>T

As numerous genetic variations in *SCN5A* (ENSG00000183873.11), encoding the primary cardiac sodium channel Nav1.5, have been linked to a number of arrhythmogenic diseases it is likely that malfunction of Nav1.5 may also play a role in AVNRT. A total of seven variants in *SCN5A* were found in the 284 AVNRT patients. Four of these have previously been functionally characterised by patch-clamping and the fifth has a stop-gain translation impact, indicating a compromised sodium channel function [20,21].
The *in vitro* electrophysiological characteristics of c.1381C>T (p.(Leu461Val)) and c.1576C>T (p.(Arg526Cys)) were studied by patch-clamping following transient expression in HEK293 cells (**Figure 3**). Whole-cell sodium currents from WT and variant channels in response to depolarizing pulses from -70 mV to + 50 mV are shown in **Figure 3A**. Peak current density was significantly increased for c.1381C>T (p.(Leu461Val)) but not for c.1576C>T (p.(Arg526Cys)) (**Supplementary Table 5).** Activation and inactivation together with time-dependent inactivation (onset of inactivation) and recovery from

217 inactivation, as well as sustained current measurements were performed. However, none of these

218 investigations revealed a difference between wild type and variant channels.

219

220 **Burden tests**

221 After exclusion of family members and ethnic outliers the dataset consisted of 284 AVNRT cases versus

222 377 controls.

223 There was no significant enrichment of rare variants in the tested genes after adjusting for multiple

224 testing, see **Supplementary Table 6 and 7**.

225

Discussion

In total, we identified 229 variants in 184 patients; 215 missense, four frame shift, four codon deletions, three missense and splice sites, two stop-gain variants, and one start-lost variant. Sixty-five of these were not present in ExAC.

A recent study by Hasdemir et al. found a phenotypic overlap between 17 patients with AVNRT and Brugada Syndrome (BrS), and following genetic screening recognized a high proportion of sodium channel variation in this cohort [22]. Their findings indicate a possible sodium channel abnormality in AVNRT patients.

Here we give a descriptive study that characterize the genetic component of AVNRT, with a focus on variation in *SCN5A* as affected conduction velocity was considered a possible disease mechanism.

A total of seven variants in *SCN5A* were found in the 284 AVNRT patients. Four of these have previously been functionally characterised by patch-clamping and the fifth has a stop-gain translation impact, indicating a compromised sodium channel function [20,21]. In a study on sudden infant death syndrome (SIDS), Wang et al. described the c.6010T>C (p.(Phe2004Leu), variant in *SCN5A* to have a gain-of-function effect [21]. The c.1019G>A (p.(Arg340Gln) variant in *SCN5A* has been associated with SIDS [21] and Long QT Syndrome 3 and has been shown to induce a negative voltage-shift of both steady-state activation and inactivation together with a reduced time constant for onset of fast inactivation [20]. We performed functional studies on two of the remaining variants. Our functional studies of c.1381C>T (p.(Leu461Val)) and c.1576C>T (p.(Arg526Cys)) in *SCN5A* (ENST00000413689) revealed an increased current density for c.1576C>T, while c.1381C>T was not found to have altered current characteristics on the parameters tested. Our subsequent principal component analysis (PCA) indicated that the carrier had a mixed ethnic background (**Supplementary Figure 5a)** and further analyses of the variant showed a MAF > 1% within an Afro-American cohort [23] . We identified 16 variants in the *SCN10A* gene, whereof four had been functionally characterized in previous studies and the fifth has a stop-gain translation impact [24,25].

Although functional characterization not equals causality, our results might indicate that altered sodium current predispose for AVNRT by affecting the conduction velocity due to potential disease modifiers in sodium handling genes. Independent replication of these results is, however, needed in larger cohorts.

254 It is also noteworthy that we identified two loss-of-function (LOF) variants in the *KCNE3* gene, which has
255 only three reported LOF variants in the ExAC database.
256 It is difficult to conclude on these findings, but nevertheless interesting.
257 Several studies have found AVNRT in AF patients, and this overlap in arrhythmia phenotype may support
258 an overlap in disease mechanisms [25–27]. This suggested common disease mechanism is supported by the
259 fact that several studies have demonstrated frequent sodium channel variants in AF patients. The results
260 from the present study combined with the data by Jabbari et al. who sequenced 225 early-onset lone AF
261 patients and found 11 patients with rare variants in *SCN10A* of which three (27%) had an AVNRT
262 diagnosis as well, despite all of them being diagnosed with AF before the age of 36 [25], further supports
263 the involvement of sodium channels in the pathophysiology of AVNRT.
264 Some of our AVNRT probands carried variants in the *HCN1-4* genes, which all have been found to have a
265 high intolerance to variation (a positive Z-score up to 7.27 for *HCN2* in the ExAC browser [23]). The *HCN2*
266 and *HCN4* genes have previously been associated with sinoatrial nodal dysfunction and the *HCN* genes
267 have an important role in the contractility of the heart muscle by restoring the resting membrane
268 potential in cardiomyocytes from hyperpolarized potentials as well as contributing to the next
269 depolarization [28].
270 Interestingly, the c.2623C>T (p.(Pro875Ser), ENST00000435607) variant in *SCN4A* co-segregated in a
271 family with three AVNRT patients, a mother and her two daughters, see **Figure 2**. Traditionally, the
272 *SCN4A* gene is not considered a main contributor to the electrophysiology of the heart, but our findings,
273 although only hypothesis generating, might indicate a role for $Na_v1.4$ in the atria.
274 One of the challenges with AVNRT is that its definite diagnosis requires invasive electrophysiological
275 study (EPS) or an oesophageal ECG recording. To obtain the highest degree of correct clinical phenotype
276 in this study we required that patients had an invasive EPS demonstrating AVNRT and following this the
277 patients had a radiofrequency catheter ablation performed. By these relatively strong inclusion criteria
278 we have minimized the risk of misdiagnosis of tachyarrhythmia subtype.
279 It is important to consider that studies have found an overrepresentation of previously phenotype-
280 associated genetic variants in the general population [29,30]. This indicates that some of these genetic
281 variants might not be monogenic causes of disease. Also, the functional analyses performed in this study

282 used a conventional heterologous expression system; hence, the environments differ from that in native
283 cardiomyocytes. Lastly, as dual AV nodal physiology can be asymptomatic, it would be interesting to test
284 control subjects for dual AV nodal physiology in a larger study setup.
285 This is, to our knowledge, the first study where the primary aim was to investigate the genetic
286 component in AVNRT using a NGS approach. We have given a descriptive report of variants seen in
287 genes responsible for the sodium of the heart, many of which have been functionally characterized.
288 Furthermore, we report two AVNRT families with co-segregating variants. Despite of familial clustering,
289 we are not able to detect a single gene or gene family to be involved with AVNRT, however, we do
290 report several interesting findings of rare genetic variation in AVNRT. The data suggest that some
291 patients with AVNRT have genetic variants that can potentially affect sodium handling, possibly by
292 affecting the conduction velocity and the refractory period. The genetic picture is, however, still
293 complex, and structural genes might play a larger role in cardiac arrhythmias than previously thought. As
294 this is only the beginning of the genetic investigation of AVNRT, the need for further genetic studies is
295 needed.
296
297 **Acknowledgements**
298 This work was supported by a framework grant of the Danish National Research Foundation, the Danish
299 Council for Independent Research (DFF-1331-00313B), The Lundbeck Foundation, The Villadsen Family
300 Foundation, The John and Birthe Meyer Foundation, The Arvid Nilsson Foundation, Direktør Ib
301 Henriksens Fond and Fondsbørsvekselerer Henry Hansen og Hustru Karla Hansen, født Westergaards,
302 legat, and The Research Council at Rigshospitalet.
303
304 **Conflict of Interest**
305 None.
306
307 **Supplementary information** is available at *European Journal of Human Genetic*'s website.
308
309

310 **References**

311 1 Katritsis DG, Camm AJ. Classification and differential diagnosis of atrioventricular nodal re-entrant
312 tachycardia. *Europace* 2006; **8**: 29–36.

313 2 Katritsis DG, Camm AJ. Atrioventricular Nodal Reentrant Tachycardia. *Circulation* 2010; **122**: 831–
314 840.

315 3 Kwaku KF, Josephson ME. Typical AVNRT--an update on mechanisms and therapy. *Card*
316 *Electrophysiol Rev* 2002; **6**: 414–421.

317 4 Marchlinski FE. Diagnosing the mechanism of supraventricular tachycardia: restoring the luster of a
318 fading art. *J Am Coll Cardiol* 2009; **53**: 2359–2361.

319 5 Medi C, Kalman JM, Freedman SB. Supraventricular tachycardia. *Med J Aust* 2009; **190**.
320 https://www.mja.com.au/journal/2009/190/5/supraventricular-tachycardia (accessed 11 Feb2014).

321 6 Akhtar M, Jazayeri MR, Sra J, Blanck Z, Deshpande S, Dhala A. Atrioventricular nodal reentry
322 (AVNRT) Clinical, electrophysiological, and therapeutic considerations. *Circulation* 1993; **88**: 282–
323 295.

324 7 Hayes JJ, Sharma PP, Smith PN, Vidaillet HJ. Familial atrioventricular nodal reentry tachycardia.
325 *Pacing Clin Electrophysiol PACE* 2004; **27**: 73–76.

326 8 Lu CW, Wu MH, Chu SH. Paroxysmal supraventricular tachycardia in identical twins with the same
327 left lateral accessory pathways and innocent dual atrioventricular pathways. *Pacing Clin*
328 *Electrophysiol PACE* 2000; **23**: 1564–1566.

329 9 Michowitz Y, Anis-Heusler A, Reinstein E, Tovia-Brodie O, Glick A, Belhassen B. Familial Occurrence
330 of Atrioventricular Nodal Reentrant Tachycardia. *Circ Arrhythm Electrophysiol* 2017; **10**: e004680.

331 10 Øyen N, Ranthe MF, Carstensen L *et al.* Familial Aggregation of Lone Atrial Fibrillation in Young
332 Persons. *J Am Coll Cardiol* 2012; **60**: 917–921.

333 11 Authors/Task Force Members, Priori SG, Blomström-Lundqvist C *et al.* 2015 ESC Guidelines for the
334 management of patients with ventricular arrhythmias and the prevention of sudden cardiac death:
335 The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of
336 Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for
337 European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2015; **36**: 2793-867.

338 12 Sajadieh A, Nielsen OW, Rasmussen V, Hein HO, Hansen JF. Prevalence and prognostic significance
339 of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart
340 disease. *Eur Heart J* 2005; **26**: 1402–1409.

341 13 Pfeufer A, van Noord C, Marciante KD *et al.* Genome-wide association study of PR interval. *Nat*
342 *Genet* 2010; **42**: 153–159.

343 14 Greener ID, Monfredi O, Inada S *et al.* Molecular architecture of the human specialised
344 atrioventricular conduction axis. *J Mol Cell Cardiol* 2011; **50**: 642–651.

345 15 Agilent. HaloPlex Target Enrichment System.
346 http://www.chem.agilent.com/library/usermanuals/Public/G9900-90001.pdf (accessed 17
347 Mar2014).

348 16 DePristo MA, Banks E, Poplin R *et al.* A framework for variation discovery and genotyping using
349 next-generation DNA sequencing data. *Nat Genet* 2011; **43**: 491–498.

350 17 Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing toolset
351 for relatedness and principal component analysis of SNP data. *Bioinforma Oxf Engl* 2012; **28**: 3326–
352 3328.

353 18 Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association tests for the
354 combined effect of rare and common variants. *Am J Hum Genet* 2013; **92**: 841–853.

355 19 Bioconductor - GENESIS (development version).
356 https://www.bioconductor.org/packages/devel/bioc/html/GENESIS.html (accessed 11 Aug2017).

357 20 Olesen MS, Yuan L, Liang B *et al.* High prevalence of long QT syndrome-associated SCN5A variants in
358 patients with early-onset lone atrial fibrillation. *Circ Cardiovasc Genet* 2012; **5**: 450–459.

359 21 Wang DW, Desai RR, Crotti L *et al.* Cardiac sodium channel dysfunction in sudden infant death
360 syndrome. *Circulation* 2007; **115**: 368–376.

361 22 Hasdemir C, Payzin S, Kocabas U *et al.* High prevalence of concealed Brugada syndrome in patients
362 with atrioventricular nodal reentrant tachycardia. *Heart Rhythm* 2015; **12**: 1584–1594.

363 23 ExAC Browser. http://exac.broadinstitute.org/ (accessed 11 Sep2015).

364 24 Savio-Galimberti E, Weeke P, Muhammad R *et al.* SCN10A/Nav1.8 modulation of peak and late
365 sodium currents in patients with early onset atrial fibrillation. *Cardiovasc Res* 2014; **104**: 355–363.

366 25 Jabbari J, Olesen MS, Yuan L *et al.* Common and Rare Variants in SCN10A Modulate the Risk of Atrial
367 Fibrillation. *Circ Cardiovasc Genet* 2015; **8**: 64-73.

368 26 Palma EC, Ferrick KJ, Gross JN, Kim SG, Fisher JD. Transition from atrioventricular node reentry
369 tachycardia to atrial fibrillation begins in the pulmonary veins. *Circulation* 2000; **102**: 937.

370 27 Brugada J, Mont L, Matas M, Navarro-López F. Atrial fibrillation induced by atrioventricular nodal
371 reentrant tachycardia. *Am J Cardiol* 1997; **79**: 681–682.

372 28 Günther A, Baumann A. Distinct expression patterns of HCN channels in HL-1 cardiomyocytes. *BMC
373 Cell Biol* 2015; **16**: 18.

374 29 Andreasen C, Nielsen JB, Refsgaard L *et al.* New population-based exome data are questioning the
375 pathogenicity of previously cardiomyopathy-associated genetic variants. *Eur J Hum Genet* 2013; **21**:
376 918–928.

377 30 Ghouse J, Have CT, Weeke P *et al.* Rare genetic variants previously associated with congenital forms
378 of long QT syndrome have little or no effect on the QT interval. *Eur Heart J* 2015; **36**: 2523–2529.

379

380 **Titles and legends to figures**

381 **Figure 1.** Diagram for the bioinformatics pipeline of sequence data. Data processing starts with raw
382 reads from the Next-Generation Sequencing. Reads, alignments, and variant calls are quality
383 controlled (QC) in intermediate steps. Variants that are of interest for further analyses are obtained
384 from a high quality genotype set at end of pipeline.

385

386 **Figure 2.** Pedigrees of the families with found variants and a history of AVNRT.

387

388 **Figure 3.** Electrophysiological effects of $Na_v1.5$-WT, L461V and R526C on sodium channel current
389 (I_{Na}). Whole-cell patch clamp analyses of transiently transfected HEK-293 cells. **A**: Representative I_{Na}
390 traces in cells expressing WT or mutants. **B**: Peak current-voltage relationship measured at -20 mV
391 for $Na_v1.5$-WT (n=7), L461V (n=10), and R526C (n=7). Currents were normalized to membrane
392 capacitance. R526C was significantly different from WT (**P* <.05). **C**, **D**: Voltage dependence of
393 activation and inactivation for $Na_v1.5$ of the 3 groups, indicating gating properties of channel
394 conductance and availability. The normalized values have been calculated by dividing the current
395 level at the respective voltage by the maximal current of the whole voltage range (I/I_{max}). Boltzmann
396 curves were fitted to both steady-state activation and inactivation data. Averaged values and the
397 number of cells used are represented in **Supplementary Table 5**. **E**: Time dependent of recovery
398 from fast inactivation of 3 groups determined using a two-pulse protocol. Data were fitted with a
399 single exponential equation. Time constants are listed in **Supplementary Table 5**. The applied
400 voltage-clamp protocols in inset of the respective figure. Of note, a recovery potential of -80 mV was
401 applied in order to mimic the resting membrane potential in the human atrial myocytes. **F**: Sustained
402 (late) Na^+ current as percentage of peak current measured following 330-350 ms depolarisations to -
403 20 mV. **G**: Onset (decay) of inactivation following depolarising pulses to either -20 mV, 0 mV or 20

404 mV. **C** and **D** were analysed by Student's unpaired *t*-test. **E**, **F** and **G** were analysed by one-way

405 ANOVA repeated measures with Dunnett's post-test.


Illumina sequencing
Trim & Cut
(Cutadapt,Prinsseq)
QC
Alignment (bwa)
fwd&rev
Indel realignment
(GATK)
Base Quality
Score Recalibration
(GATK)
Joint genotyping,
SNPs & INDELS
(UnifiedGenotyper
GATK)
Filtering Variants
Annotation
(snpEFF)
Extracting rare variants
with predicted impact
High or Moderate
Potential functional
variants



Patient 1
?
I-1
I-2
Not available for genetic testing
II-2
II-1
SCN4A P87S (+ / -)
RYR3 R1200C (+ / -)
III-1
SCN4A P87S (+ / -)
SCN5A F2004L (+ / -)
III-2
SCN4A P87S (+ / -)
RYR3 R1200C (+ / -)
SCN5A F2004L (+ / -)
Male
Female
Proband
(+ / -) Presence / absense of genetic variation
AVNRT
Unaffected individual



Patient 2
I-1
I-2
CAV3 T78M (+ / -)
II-1
CAV3 T78M (+ / -)


A)
WT
L461V
R526C
2 nA
5 ms


B)
Vm (mV)
-50
-25
0
25
50
0
-150
-300
Current Density (pA/pF)


C)
Normalized Conductance
350ms
50mV
-70mV
-120mV
Vm (mV)


D)
Normalized Currents
20ms
-10mV
-80mV
-140mV
500ms
Vm (mV)


E)
Normalized Currents
-20mV
500ms
50ms
-80mV
-100mV
△t(1-600ms)
Time (ms)


F)
Sustained/Peak Current (%)
n=6
n=9
n=6
WT
L461V
R526C


G)
Tau(ms)
Vm (mV)

Table 1. Target genes studied in AVNRT patients

Gene	Ensembl gene id	Ref
ARHGAP24	ENSG00000138639.13	(13)
CAV1	ENSG00000105974.7	
CAV2	ENSG00000105971.10	
MEIS1	ENSG00000143995.15	
NKX2-5	ENSG00000183072.9	
SCN10A	ENSG00000185313.6	
SOX5	ENSG00000134532.11	
TBX3	ENSG00000135111.10	
TBX5	ENSG00000089225.15	
WNT11	ENSG00000085741.8	
ADRB1	ENSG00000043591.4	(14)
ADRB2	ENSG00000169252.4	
ATP2A2	ENSG00000174437.12	
CACNA1C	ENSG00000151067.16	
CACNA1D	ENSG00000157388.9	
CACNA1G	ENSG00000006283.13	
CACNA1I	ENSG00000100346.13	
DPP6	ENSG00000130226.12	
ERG	ENSG00000157554.14	
GJA1	ENSG00000152661.7	
GJA5	ENSG00000143140.6	
GJC1	ENSG00000182963.5	
GJD3	ENSG00000183153.5	
HCN1	ENSG00000164588.4	
HCN2	ENSG00000099822.2	
HCN3	ENSG00000263324.1	
HCN4	ENSG00000138622.3	
ITPR1	ENSG00000150995.13	
KCNA4	ENSG00000182255.6	
KCNA5	ENSG00000130037.3	
KCNAB1	ENSG00000169282.13	
KCNAB2	ENSG00000069424.10	
KCND2	ENSG00000184408.5	
KCND3	ENSG00000171385.5	
KCNE1	ENSG00000180509.7	
KCNJ12	ENSG00000184185.5	
KCNJ2	ENSG00000123700.4	
KCNJ3	ENSG00000162989.3	
KCNJ4	ENSG00000168135.4	
KCNJ5	ENSG00000120457.7	
KCNQ1	ENSG00000053918.11	
NPPA	ENSG00000175206.6	
PIAS3	ENSG00000131788.11	
RYR2	ENSG00000198626.11	

RYR3	ENSG00000198838.7	
SCN1A	ENSG00000144285.11	
SCN1B	ENSG00000105711.6	
SCN2B	ENSG00000149575.5	
SCN3A	ENSG00000153253.11	
SCN3B	ENSG00000166257.4	
SCN4A	ENSG00000007314.7	
SCN4B	ENSG00000177098.4	
SCN5A	ENSG00000183873.11	
SCN8A	ENSG00000196876.9	
SCN9A	ENSG00000169432.10	
SLC8A1	ENSG00000183023.14	
AKAP9	ENSG00000127914.12	
ANK2	ENSG00000145362.12	
CACNB2	ENSG00000165995.14	
CASQ2	ENSG00000118729.10	
CAV3	ENSG00000182533.6	
GPD1L	ENSG00000152642.6	†
KCNE2	ENSG00000159197.3	
KCNE3	ENSG00000175538.6	
KCNH2	ENSG00000055118.10	
NCS1	ENSG00000107130.6	
SNTA1	ENSG00000101400.5	

AVNRT, AV nodal reentry tachycardia. † Plausible genes based on protein function and association with other arrhythmic diseases.

Table 2. Clinical data of the AVNRT population.

	AVNRT
N	298
Median age at AVNRT associated symptom onset, y (IQR)	24 (11-41)
Female gender, %	70
Height, cm	173 (9)
Weight, kg	76 (16)
BMI	25 (5)
Blood pressure, mmHg	
Systolic	131 (15)
Diastolic	80 (11)
Smoking, %	22
Syncope, %	14
1st degree relative(s) with cardiac arrhythmia, self-reported, %	30

All data are presented as mean (SD) unless otherwise indicated. AF, atrial fibrillation; AVNRT, AV nodal reentry tachycardia; BMI, body mass index (calculated as weight [kg] / height^2 [m^2]; IQR, interquartile range.